Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 3;12(10):e0185708.
doi: 10.1371/journal.pone.0185708. eCollection 2017.

TLR9 stimulation of B-cells induces transcription of p53 and prevents spontaneous and irradiation-induced cell death independent of DNA damage responses. Implications for Common variable immunodeficiency

Affiliations

TLR9 stimulation of B-cells induces transcription of p53 and prevents spontaneous and irradiation-induced cell death independent of DNA damage responses. Implications for Common variable immunodeficiency

Kristine Lillebø Holm et al. PLoS One. .

Abstract

In the present study, we address the important issue of whether B-cells protected from irradiation-induced cell death, may survive with elevated levels of DNA damage. If so, such cells would be at higher risk of gaining mutations and undergoing malignant transformation. We show that stimulation of B-cells with the TLR9 ligands CpG-oligodeoxynucleotides (CpG-ODN) prevents spontaneous and irradiation-induced death of normal peripheral blood B-cells, and of B-cells from patients diagnosed with Common variable immunodeficiency (CVID). The TLR9-mediated survival is enhanced by the vitamin A metabolite retinoic acid (RA). Importantly, neither stimulation of B-cells via TLR9 alone or with RA increases irradiation-induced DNA strand breaks and DNA damage responses such as activation of ATM and DNA-PKcs. We prove that elevated levels of γH2AX imposed by irradiation of stimulated B-cells is not due to induction of DNA double strand breaks, but merely reflects increased levels of total H2AX upon stimulation. Interestingly however, we unexpectedly find that TLR9 stimulation of B-cells induces low amounts of inactive p53, explained by transcriptional induction of TP53. Taken together, we show that enhanced survival of irradiated B-cells is not accompanied by elevated levels of DNA damage. Our results imply that TLR9-mediated activation of B-cells not only promotes cell survival, but may via p53 provide cells with a barrier against harmful consequences of enhanced activation and proliferation. As CVID-derived B-cells are more radiosensitive and prone to undergo apoptosis than normal B-cells, our data support treatment of CVID patients with CpG-ODN and RA.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: HKB is a share-holder of AS Vitas. AS Vitas has no part or role in this study. We confirm that this commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials. SS and AC have shares in Norgenotech AS (Comet Biotech AS is a daughter company). These companies are engaged in research activities and have been involved in various EC and national studies, including Norwegian SkatteFunn tax deduction scheme awarded to R&D carrying SMEs. Their financial involvement in research is limited by covering salaries and materials for their employees. These companies have never been acting as funders and have no commercial interest in outcomes of the research projects they participate in. In this particular study AC and SS have been involved in all of the aspects connected with carrying out the comet assay on the samples of cells, which included the design of the comet assay experiments (including x-irradiation doses and conditions), carrying out the experimental part, data collection and analysis, general scientific discussions and manuscript preparation. Norgenotech & Comet Biotech financial involvement in the study: salary for SS and coverage of the reagents, materials, lab rent and technical assistance connected with carrying out the experiments (these actual costs of Norgenotech were covered by the University of Oslo with no commercial profit or overheads). Thus both AC and SS have no commercial or financial interests in the study outcomes, and their affiliated companies have not acted as funders in the study. Finally, we confirm that this commercial affiliation does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. RA reduces spontaneous and irradiation-induced apoptosis of normal and CVID-derived B-cells stimulated via TLR9.
Normal and CVID-derived B-cells were treated with CpG-ODN (0.5 μg/ml) in the presence or absence of RA (200 nM) for 24 hours prior to irradiation (IR; 10 Gy). After additional 24 hours, cell death was measured as the percentage of PI-positive cells. Each symbol represents the data from an individual patient or healthy control, and the horizontal lines represent median values, (n = 7, *p < 0.05, Wilcoxon signed rank test).
Fig 2
Fig 2. TLR9 stimulation induces p53 expression.
(A) Normal B-cells were treated with CpG-ODN (0.5 μg/ml) in the presence or absence of RA (200 nM) for 24 hours prior to irradiation (IR; 10 Gy). After indicated time points B-cells were collected and subjected to western blot analysis with antibodies recognizing calnexin (as loading control), p53, or p53 phosphorylated at serine 15 (S15). The right panel shows a more exposed version of the blot depicting induction of p53 in non-irradiated cells. One representative experiment of three is shown. Original uncropped blots are presented in S5 Fig. (B) Densitometric analysis of the p53 expression (based on low exposure) at 4 hours after irradiation was normalized to calnexin. The results are presented as histograms of mean values ±SEM (n = 6, *p < 0.05, **p < 0.01, paired t-test). (C) B-cells were treated as described in (A), and lysates were subjected to western blot analysis with antibodies recognizing calnexin (as loading control) and p21Cip. One representative experiment of three is shown. Original uncropped blots are presented in S6 Fig. (D) B-cells were stimulated as described in (A), and the cells were harvested 24 hours after irradiation. The mRNA level of TP53 was quantified by RT-qPCR. The amounts of TP53 mRNA related to reference genes (TBP and B2M) were quantified using the 2-ΔCt-method. The results are presented as histograms of mean values ±SEM (n = 4 *p < 0.05, paired t-test).
Fig 3
Fig 3. TLR9 stimulation does not activate DDRs upstream of p53.
(A) B-cells were treated with CpG-ODN (0.5 μg/ml) in the presence or absence of RA (200 nM) for 24 hours prior to irradiation (IR; 10 Gy). After indicated time points, B-cells were collected and subjected to western blot analysis with antibodies recognizing calnexin (as loading control) and phosphorylated ATM (S1981). One representative experiment of three is shown. Original uncropped blots are presented in S7 Fig. (B) Densitometric analysis of pATM expression at 0.5 hours after irradiation was normalized to calnexin. The results are presented as histograms of mean values ±SEM (n = 5, *p < 0.05, paired t-test). (C) B-cells were treated as indicated in (A), and the B-cells were harvested one hour after irradiation and subjected to western blot analysis with antibodies recognizing calnexin (as loading control), pDNA-PKcs (S2056, upper panel) and pATR (Thr1989, lower panel). One representative experiment of three is shown. Original uncropped blots are presented in S8 Fig.
Fig 4
Fig 4. TLR9 stimulation enhances the levels of H2AX in B-cells.
(A) B-cells were treated with CpG-ODN (0.5 μg/ml) in the presence or absence of RA (200 nM) for 24 hours prior to irradiation (IR; 10 Gy). After indicated time points, ethanol-fixed samples were bar-coded with pacific blue and four samples were mixed into a single tube before staining with antibodies recognizing γH2AX and DNA stain FxCycleTM Far Red. The median level of γH2AX was analyzed using flow cytometry. The histogram represents average of median levels of γH2AX ±SEM at indicated time points after irradiation related to non-irradiated cells (n = 3, *p < 0.05, **p < 0.01, paired t-test). (B) B-cells were treated as indicated in (A) and fixed with ethanol 2 hours after irradiation. The samples were barcoded and three samples were mixed in one tube before staining with antibodies recognizing H2AX and DNA stain FxCycleTM Far Red. The histograms present average of median levels of H2AX related to non-irradiated cells ±SEM (n = 4, *p < 0.05, **p < 0.01, paired t-test).
Fig 5
Fig 5. TLR9 stimulation does not enhance DNA damage-induced DNA strand breaks.
B-cells were treated with CpG-ODN (0.5 μg/ml) in the presence or absence of RA (200 nM) for 24 hours prior to irradiation (IR; 5 Gy). After indicated time points the cells were lysed, and single cell gel electrophoresis was performed. DNA was stained with SYBRgold, and DNA damage was estimated measuring the % DNA in the tail. (A) Pictures of representative comets from non-irradiated and irradiated cells. One representative experiment is shown. (B) The results (% DNA in tails) are presented as histograms of mean values ±SEM (n = 4, *p < 0.05, paired t-test).

Similar articles

Cited by

References

    1. Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med 2015;66:129–43. doi: 10.1146/annurev-med-081313-121208 - DOI - PubMed
    1. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010. October 22;40(2):179–204. doi: 10.1016/j.molcel.2010.09.019 - DOI - PMC - PubMed
    1. Lindahl T. Instability and decay of the primary structure of DNA. Nature 1993. April 22;362(6422):709–15. doi: 10.1038/362709a0 - DOI - PubMed
    1. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009. October 22;461(7267):1071–8. doi: 10.1038/nature08467 - DOI - PMC - PubMed
    1. Kamran SC, Berrington de GA, Ng A, Haas-Kogan D, Viswanathan AN. Therapeutic radiation and the potential risk of second malignancies. Cancer 2016. June 15;122(12):1809–21. doi: 10.1002/cncr.29841 - DOI - PubMed

MeSH terms